292 related articles for article (PubMed ID: 2730018)
21. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
Chen SB
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
24. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
25. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of serum DU-PAN-2 surveyed by solid-phase sandwich EIA for DU-PAN-2].
Ishii M; Urabe T; Seino Y
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1860-5. PubMed ID: 3296960
[TBL] [Abstract][Full Text] [Related]
27. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
J Med; 1991; 22(3):145-56. PubMed ID: 1770322
[TBL] [Abstract][Full Text] [Related]
28. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
29. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
31. [The concentration of carcinoembryonic antigen and carbohydrate antigen Ca-19-9 in the blood serum in cancerous diseases of the gastrointestinal tract].
Mit'kov VV; Ogneva TV; Goriaĭnova II; Milanov S; Milkov V
Med Radiol (Mosk); 1989 Nov; 34(11):22-4. PubMed ID: 2586258
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
[TBL] [Abstract][Full Text] [Related]
33. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
Tappero G; Piantino P; Cerchier A; Pecchio F
Minerva Med; 1985 Apr; 76(16):765-70. PubMed ID: 2582313
[TBL] [Abstract][Full Text] [Related]
34. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
35. [Clinical investigation of carbohydrate antigen CA-50].
Ishii M; Abe O; Okura H; Okazaki N; Kawai T; Saito Y; Sawabu N; Takamizawa Y; Takeuchi T; Niitani H
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2548-55. PubMed ID: 3304170
[TBL] [Abstract][Full Text] [Related]
36. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
Ohuchi N; Matoba N; Taira Y; Takahashi K; Sakai N; Sato K; Fujita N; Mochizuki F; Nishihira T; Mori S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
[TBL] [Abstract][Full Text] [Related]
37. [Determination of serum DU-PAN-2 by enzyme immunoassay in patients with various digestive cancers].
Takemori Y; Sawabu N; Satomura Y; Ohta H; Watanabe H; Okai T; Mai M; Hattori N; Akiyama T; Hashimoto T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):119-26. PubMed ID: 3541791
[TBL] [Abstract][Full Text] [Related]
38. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G
Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
Noda K; Shiota M; Tanizawa O; Inoue M; Tenjin Y; Sugishita T; Yakushiji M; Miyoshi T; Nozawa S; Sakuma T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
Olsson NO; Crimet-Montange D; Martin F
Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
